{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:32:18Z","timestamp":1794321138751,"version":"4.9.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Administration of Traditional Chinese Medicine","award":["CXZH2024043"],"award-info":[{"award-number":["CXZH2024043"]}]},{"name":"Beijing University of Chinese Medicine's Leading Project","award":["2024-JYB-JBZD-003"],"award-info":[{"award-number":["2024-JYB-JBZD-003"]}],"id":[{"id":"https:\/\/ror.org\/05damtm70","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s10557-026-07885-4","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:01:28Z","timestamp":1781917288000},"page":"2365-2392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Cardiovascular, Lipid, and Safety Effects of Lipid-Modifying Therapies in Diabetes: An Agent-, Class-, and Dose-Level Network Meta-Analysis"],"prefix":"10.1007","volume":"40","author":[{"given":"Xudong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiafan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuijuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruigeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushang","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shidong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"key":"7885_CR1","volume-title":"IDF diabetes atlas 11th edition 2025: global prevalence and projections for 2050","author":"BB Duncan","year":"2025","unstructured":"Duncan BB, Magliano DJ, Boyko EJ. IDF diabetes atlas 11th edition 2025: global prevalence and projections for 2050. Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association.: Nephrology; 2025."},{"issue":"10","key":"7885_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41569-023-00877-z","volume":"20","author":"ND Wong","year":"2023","unstructured":"Wong ND, Sattar N. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nat Rev Cardiol. 2023;20(10):685\u201395.","journal-title":"Nat Rev Cardiol"},{"key":"7885_CR3","volume-title":"Guidelines for the Management of High Blood Cholesterol","author":"KR Feingold","year":"2025","unstructured":"Feingold KR. Guidelines for the Management of High Blood Cholesterol. South Dartmouth (MA): MDText.com, Inc.; 2025."},{"issue":"1 Suppl 1","key":"7885_CR4","first-page":"S207","volume":"48","author":"10","year":"2025","unstructured":"10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S207\u201338.","journal-title":"Diabetes Care"},{"issue":"6","key":"7885_CR5","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s10557-024-07587-9","volume":"39","author":"C Chen","year":"2024","unstructured":"Chen C, Wei F-F, Dong Y, Liu C. Early management of blood lipid levels with non-statin lipid-lowering drugs in Acute Coronary Syndrome: a mini review. Cardiovasc Drugs Ther. 2024;39(6):1465\u201380.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"7885_CR6","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s10557-024-07599-5","volume":"39","author":"D Grejtakova","year":"2024","unstructured":"Grejtakova D, Boronova I, Bernasovska J, Bellosta S. PCSK9 and lipid metabolism: genetic variants, current therapies, and cardiovascular outcomes. Cardiovasc Drugs Ther. 2024;39(6):1439\u201351.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7885_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2023.117187","volume":"394","author":"XH Yang","year":"2024","unstructured":"Yang XH, Tu QM, Li L, Guo YP, Wang NS, Jin HM. Triglyceride-lowering therapy for the prevention of cardiovascular events, stroke, and mortality in patients with diabetes: a meta-analysis of randomized controlled trials. Atherosclerosis. 2024;394:117187.","journal-title":"Atherosclerosis"},{"issue":"4","key":"7885_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/ehjcvp\/pvad019","volume":"9","author":"E Imbalzano","year":"2023","unstructured":"Imbalzano E, Ilardi F, Orlando L, Pintaudi B, Savarese G, Rosano G. The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2023;9(4):318\u201327.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"11","key":"7885_CR9","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1016\/j.numecd.2022.07.018","volume":"32","author":"XH Yang","year":"2022","unstructured":"Yang XH, Zhang BL, Cheng Y, Fu SK, Jin HM. Statin use and the risk of CVD events, stroke, and all-cause mortality in patients with diabetes: a systematic review and meta-analysis. Nutr Metab Cardiovasc Dis. 2022;32(11):2470\u201382.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"7885_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1155\/2020\/3987065","volume":"2020","author":"XD Zhang","year":"2020","unstructured":"Zhang XD, Xing L, Jia XN, et al. Comparative Lipid-Lowering\/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials. Cardiovasc Ther. 2020;2020:21.","journal-title":"Cardiovasc Ther"},{"key":"7885_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520926349","author":"C Zhai","year":"2020","unstructured":"Zhai C, Hou K, Li R, et al. Efficacy of statin treatment based on cardiovascular outcomes in elderly patients: a standard meta-analysis and Bayesian network analysis. J Int Med Res. 2020;48(6):300060520926349. https:\/\/doi.org\/10.1177\/0300060520926349","journal-title":"J Int Med Res"},{"key":"7885_CR12","first-page":"n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Res ed). 2021;372:n71.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"11","key":"7885_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"key":"7885_CR14","first-page":"l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical Res ed). 2019;366:l4898.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"1","key":"7885_CR15","volume":"16","author":"T Papakonstantinou","year":"2020","unstructured":"Papakonstantinou T, Nikolakopoulou A, Higgins JPT, Egger M, Salanti G. CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis. Campbell Syst Rev. 2020;16(1):e1080.","journal-title":"Campbell Syst Rev"},{"issue":"4","key":"7885_CR16","doi-asserted-by":"publisher","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A, Higgins JPT, Papakonstantinou T, et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17(4):e1003082.","journal-title":"PLoS Med"},{"key":"7885_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"7885_CR18","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2016","unstructured":"Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res. 2016;27(6):1785\u2013805.","journal-title":"Stat Methods Med Res"},{"key":"7885_CR19","unstructured":"Higgins JPT, Thomas J, Chandler J et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024. Available from www.cochrane.org\/handbook"},{"issue":"2","key":"7885_CR20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.atherosclerosis.2009.03.029","volume":"206","author":"S Oikawa","year":"2009","unstructured":"Oikawa S, Yokoyama M, Origasa H, et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2009;206(2):535.","journal-title":"Atherosclerosis"},{"issue":"4","key":"7885_CR21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/jrsm.1058","volume":"3","author":"G R\u00fccker","year":"2012","unstructured":"R\u00fccker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods. 2012;3(4):312\u201324.","journal-title":"Res Synth Methods"},{"issue":"5","key":"7885_CR22","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2337\/diacare.28.5.1151","volume":"28","author":"PS Sever","year":"2005","unstructured":"Sever PS, Poulter NR, Dahl\u00f6f B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial\u2013lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005;28(5):1151\u20137.","journal-title":"Diabetes Care"},{"issue":"12","key":"7885_CR23","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941\u201350.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"7885_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S2213-8587(23)00316-9","volume":"12","author":"KK Ray","year":"2024","unstructured":"Ray KK, Nicholls SJ, Li N, et al. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diabetes Endocrinol. 2024;12(1):19\u201328.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"7885_CR25","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","volume":"7","author":"KK Ray","year":"2019","unstructured":"Ray KK, Colhoun HM, Szarek M, et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. lancet Diabetes Endocrinol. 2019;7(8):618.","journal-title":"lancet Diabetes Endocrinol"},{"issue":"16","key":"7885_CR26","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1001\/jama.2020.3308","volume":"323","author":"KK Ray","year":"2020","unstructured":"Ray KK, Nicholls SJ, Buhr KA, et al. Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients with Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. JAMA - J Am Med Association. 2020;323(16):1565\u201373.","journal-title":"JAMA - J Am Med Association"},{"issue":"11","key":"7885_CR27","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/eurheartj\/ehac709","volume":"44","author":"YJ Lee","year":"2023","unstructured":"Lee YJ, Cho JY, You SC, et al. Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial. Eur Heart J. 2023;44(11):972.","journal-title":"Eur Heart J"},{"issue":"7","key":"7885_CR28","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.2337\/dc05-2415","volume":"29","author":"RH Knopp","year":"2006","unstructured":"Knopp RH, d\u2019Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29(7):1478.","journal-title":"Diabetes Care"},{"issue":"9500","key":"7885_CR29","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (london england). 2005;366(9500):1849.","journal-title":"Lancet (london england)"},{"issue":"10","key":"7885_CR30","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.2337\/diacare.26.10.2713","volume":"26","author":"A Keech","year":"2003","unstructured":"Keech A, Colquhoun D, Best J, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003;26(10):2713\u201321.","journal-title":"Diabetes Care"},{"issue":"16","key":"7885_CR31","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","volume":"379","author":"ASC Group","year":"2018","unstructured":"Group ASC, Bowman L, Mafham M, et al. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med. 2018;379(16):1540.","journal-title":"N Engl J Med"},{"issue":"15","key":"7885_CR32","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","volume":"137","author":"RP Giugliano","year":"2018","unstructured":"Giugliano RP, Cannon CP, Blazing MA, et al. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: results From IMPROVE-IT (Improved Reduction of Outcomes: vytorin Efficacy International Trial). Circulation. 2018;137(15):1571.","journal-title":"Circulation"},{"issue":"17","key":"7885_CR33","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563\u201374.","journal-title":"N Engl J Med"},{"issue":"21","key":"7885_CR34","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","volume":"387","author":"A Das Pradhan","year":"2022","unstructured":"Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med. 2022;387(21):1923\u201334.","journal-title":"N Engl J Med"},{"issue":"9374","key":"7885_CR35","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","volume":"361","author":"R Collins","year":"2003","unstructured":"Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005\u201316.","journal-title":"Lancet"},{"issue":"9435","key":"7885_CR36","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"HM Colhoun","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685\u201396.","journal-title":"Lancet"},{"issue":"10","key":"7885_CR37","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/archneurol.2011.146","volume":"68","author":"A Callahan","year":"2011","unstructured":"Callahan A, Amarenco P, Goldstein LB, et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: Secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Arch Neurol. 2011;68(10):1245\u201351.","journal-title":"Arch Neurol"},{"issue":"2","key":"7885_CR38","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ahj.2004.03.067","volume":"149","author":"CA Arampatzis","year":"2005","unstructured":"Arampatzis CA, Goedhart D, Serruys PW, Saia F, Lemos PA, de Feyter P. Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention - a Lescol Intervention Prevention Study (LIPS) substudy. Am Heart J. 2005;149(2):329\u201335.","journal-title":"Am Heart J"},{"issue":"1","key":"7885_CR39","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10557-025-07670-9","volume":"40","author":"X Zhang","year":"2025","unstructured":"Zhang X, Cao C, Zheng F, Liu C, Tian X. Therapeutic potential of GLP-1 receptor agonists in diabetes and cardiovascular disease: mechanisms and clinical implications. Cardiovasc Drugs Ther. 2025;40(1):287\u2013301.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7885_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2020.08.009","author":"HE Bays","year":"2020","unstructured":"Bays HE, Banach M, Catapano AL, et al. Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials. J Clin Lipidol. 2020;14(5):649-659.e6. https:\/\/doi.org\/10.1016\/j.jacl.2020.08.009","journal-title":"J Clin Lipidol"},{"issue":"1","key":"7885_CR41","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12933-024-02305-z","volume":"23","author":"J-C Fruchart","year":"2024","unstructured":"Fruchart J-C, Fruchart-Najib J, Yamashita S, et al. Lessons from PROMINENT and prospects for pemafibrate. Cardiovasc Diabetol. 2024;23(1):279.","journal-title":"Cardiovasc Diabetol"},{"issue":"17","key":"7885_CR42","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1080\/10408398.2015.1130016","volume":"57","author":"OGL Coelho","year":"2017","unstructured":"Coelho OGL, da Silva BP, Rocha DMUP, Lopes LL, Alfenas R. Polyunsaturated fatty acids and type 2 diabetes: impact on the glycemic control mechanism. Crit Rev Food Sci Nutr. 2017;57(17):3614\u20139.","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"1","key":"7885_CR43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12944-020-01214-w","volume":"19","author":"C Gao","year":"2020","unstructured":"Gao C, Liu Y, Gan Y, et al. Effects of fish oil supplementation on glucose control and lipid levels among patients with type 2 diabetes mellitus: a Meta-analysis of randomized controlled trials. Lipids Health Dis. 2020;19(1):87.","journal-title":"Lipids Health Dis"},{"key":"7885_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11110742","author":"L Khalili","year":"2021","unstructured":"Khalili L, Valdes-Ramos R, Harbige LS. Effect of n-3 (Omega-3) polyunsaturated fatty acid supplementation on metabolic and inflammatory biomarkers and body weight in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of RCTs. Metabolites. 2021;11(11):742. https:\/\/doi.org\/10.3390\/metabo11110742","journal-title":"Metabolites"},{"issue":"1","key":"7885_CR45","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12933-025-02769-7","volume":"24","author":"S Scilletta","year":"2025","unstructured":"Scilletta S, Di Marco M, Miano N, et al. Cardiovascular risk profile in subjects with diabetes: Is SCORE2-Diabetes reliable? Cardiovasc Diabetol. 2025;24(1):222.https:\/\/doi.org\/10.1186\/s12933-025-02769-7","journal-title":"Cardiovasc Diabetol"},{"key":"7885_CR46","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.pcad.2025.05.008","volume":"92","author":"G Bosco","year":"2025","unstructured":"Bosco G, Di Giacomo Barbagallo F, Di Marco M, et al. Effect of inclisiran on lipid and mechanical vascular profiles in familial hypercholesterolemia subjects: results from a single lipid center real-world experience. Progress In Cardiovascular Diseases. 2025;92:108\u201317.","journal-title":"Progress In Cardiovascular Diseases"},{"issue":"8","key":"7885_CR47","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1111\/dom.15650","volume":"26","author":"LA Leiter","year":"2024","unstructured":"Leiter LA, Raal FJ, Schwartz GG, et al. Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials. Diabetes Obes Metab. 2024;26(8):3223\u201337.","journal-title":"Diabetes Obes Metab"},{"key":"7885_CR48","doi-asserted-by":"publisher","unstructured":"Sydhom P, Al-Quraishi B, Gohar A et al. The efficacy and safety of plozasiran on lipid profile in dyslipidemic disorders: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2025. https:\/\/doi.org\/10.1007\/s10557-025-07798-8","DOI":"10.1007\/s10557-025-07798-8"},{"key":"7885_CR49","doi-asserted-by":"crossref","unstructured":"Al-Horani RA, Selico-Dunn AC, Smith ELS. Lipoprotein(a) in cardiovascular diseases and emerging therapeutic strategies. Cardiovasc Drugs Ther 2025.","DOI":"10.1007\/s10557-025-07810-1"},{"issue":"2","key":"7885_CR50","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s12020-023-03401-y","volume":"81","author":"R Rodriguez-Gutierrez","year":"2023","unstructured":"Rodriguez-Gutierrez R, Garcia-Leal M, Raygoza-Cortez K, et al. Benefits and harms of fibrate therapy in patients with type 2 diabetes: a systematic review and meta-analysis. Endocrine. 2023;81(2):231\u201345.","journal-title":"Endocrine"},{"issue":"1","key":"7885_CR51","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12933-020-01101-9","volume":"19","author":"X Wang","year":"2020","unstructured":"Wang X, Zhang Y, Tan H, et al. Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2020;19(1):128.","journal-title":"Cardiovasc Diabetol"},{"issue":"9607","key":"7885_CR52","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","volume":"371","author":"PM Kearney","year":"2008","unstructured":"Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet (London England). 2008;371(9607):117\u201325.","journal-title":"Lancet (London England)"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07885-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07885-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07885-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:02:53Z","timestamp":1794319373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07885-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["7885"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07885-4","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"22 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}